A cross-sectional study on drug use in multiple system atrophy

CNS Drugs

Volumn 28, Issue 5, 2014, Pages 483-490

  Rey, María Verónica ^a,b   Perez Lloret, Santiago ^a,b   Pavy Le Traon, Anne ^a,b   Meissner, Wassilios G ^c,d,e   Tison, Francois ^c,d,e   Rascol, Olivier ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; AMANTADINE; ANALGESIC AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLUDROCORTISONE; HYPERTENSIVE AGENT; HYPNOTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; IMIPRAMINE; LAXATIVE; LEVODOPA; LEVOTHYROXINE; MIDODRINE; MONOAMINE OXIDASE B INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

AGED; ARTICLE; ATAXIA; CONSTIPATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; ORGAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; SHY DRAGER SYNDROME; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY DYSFUNCTION; AGE; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG INTERACTION; EPIDEMIOLOGY; FRANCE; MULTIPLE SYSTEM ATROPHY; REGISTER; SEVERITY OF ILLNESS INDEX;

AGE FACTORS; AGED; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; MALE; MULTIPLE SYSTEM ATROPHY; OFF-LABEL USE; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; SEVERITY OF ILLNESS INDEX;

EID: 84901500488     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0159-1     Document Type: Article

References (33)

1. Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy: an update. Lancet Neurol. 2009;8:1172-8.
2. Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord. 2005;20(Suppl 12):S67-76.
3. Lee D, Bergman U. Studies of drug utilization. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2000. p. 463-82.
4. Centre de référence de l'atrophie multysisté matisée. http://www.chu-toulouse.fr/-centre-de-reference-de-l-atrophie- multisystématisée (Accessed 2013 Oct. 15).
5. Les Maladies Rares. http://www.sante.gouv.fr/les-maladies-rares.html (Accessed 2013 Oct. 15).
6. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391-402.
7. Damon-Perriere N, Foubert-Samier A, De Cock VC, et al. Assessment of the SCOPA-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord. 2012;18:612-5.
8. Pavy-Le TA, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011;26:1985-92.
9. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-6.
10. Perez-Lloret S, Rey MV, Fabre N, et al. Do Parkinson's disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol. 2012;68:857-65.
11. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42:1142-6.
12. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012, Oslo 2011.
13. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25:2649-53.
14. Fahn S, Elton RL, Members of the UPDRS committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Mardsen CD, Goldstein M, editors. Recent developments in Parkinson's disease. New York: McMillan; 1987. p. 153-63.
15. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998;25:1032-7.
16. Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European Multiple System Atrophy Registry. Mov Disord. 2010;25:2604-12.
17. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy: American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359-62.
18. Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. CNS Drugs. 2010;24:941-68.
19. Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, et al. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111-24.
20. Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol. 2010;257:5-14.
21. Papatsoris AG, Papapetropoulos S, Singer C, et al. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn. 2008;27:22-7.
22. Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst. 2000;79:191-5.
23. Cameron AP, Jimbo M, Heidelbaugh JJ. Diagnosis and office-based treatment of urinary incontinence in adults: part two. Treatment. Ther Adv Urol. 2013;5:189-200.
24. Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol. 2004;3:93-103.
25. Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson's disease. Mov Disord. 2006;21:1056-7.
26. Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226-31.
27. Licht CM, de Geus EJ, van Dyck R, et al. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 2010;68:861-8.
28. Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614-23.
29. Chrysostome V, Tison F, Yekhlef F, et al. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology. 2004;23:201-8.
30. Farzamnia H, Rabiei K, Sadeghi M, et al. The predictive factors of recurrent deep vein thrombosis. ARYA Atheroscler. 2011;7:123-8.
31. Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077-81.
32. Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11:83-94.
33. Schmidt C, Berg D, Prieur S, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24:2136-42.